NHSO Board Approves EEG Services for Drug-Resistant Epilepsy Patients

According to a report by Matichon Online on September 2, 2026, the board of the National Health Security Office (NHSO) has reached a resolution to expand medical coverage. The board officially approved the provision of electroencephalogram (EEG) services specifically tailored for patients suffering from drug-resistant epilepsy. This decision is part of the broader fund management criteria established for the 2027 fiscal year.

For residents and long-term expatriates in Thailand, this development is significant as it reflects an ongoing effort to improve specialized neurological care within the national healthcare framework. Access to advanced diagnostic tools like EEGs is critical for managing complex conditions such as epilepsy, potentially reducing the long-term burden on patients who do not respond to standard pharmaceutical treatments.

While the board has approved the inclusion of these services, specific details regarding the implementation timeline, the exact criteria for patient eligibility, and the network of hospitals that will provide these specialized EEG services remain to be confirmed. Residents who rely on the national health scheme should monitor official NHSO announcements for updates on when these services will become accessible at local medical facilities. This update serves as a policy framework adjustment rather than an immediate change to clinical availability.